Follow us on our mission to transform
diseases with RNAa therapeutics.
Follow us on our mission to transform
diseases with RNAa therapeutics.
PRESS RELEASES
04 Apr, 2024
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases
Collaboration includes licensing agreement option based on early-stage preclinical outcomes […]
24 Jan, 2024
MiNA Therapeutics Presents New Data for its HbF Program at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference
Pre-clinical studies confirm in vivo delivery of small activating RNA therapeutics to erythroid progenitor cells at clinically meaningful levels. Compelling pre-clinical data supports advancement of MiNA’s HbF program for development in sickle cell disease and beta thalassemia […]
25 Oct, 2023
MiNA Therapeutics Highlights Preclinical Research on RNA Activation (RNAa) Therapeutics Presented at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
Findings demonstrate structure-activity relationship of RNAa therapeutics, supporting use in genetic medicine, as well as therapeutic potential of MiNA’s MTL-CEBPA in acute myeloid leukemia […]
25 Apr, 2023
MiNA Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Advance RNAa Platform Research in Rare Genetic Diseases
MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a multi-target research collaboration and option licensing agreement with BioMarin Pharmaceutical Inc. The collaboration will allow for the discovery, and potential development and commercialization of RNAa therapeutic candidates targeting a number of rare genetic diseases […]
14 Apr, 2023
MiNA Therapeutics Presents Late-Breaking Positive Phase 1b Data for MTL-CEBPA in Combination with an Anti-PD1 Checkpoint Inhibitor at the Annual American Association of Cancer Research (AACR) Meeting
MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, will present positive updated biomarker data from its Phase 1a/b TIMEPOINT study of MTL-CEBPA in combination with the anti-PD1 checkpoint inhibitor, pembrolizumab, in adults with advanced solid tumors at the annual meeting of the American Association of Cancer Research (AACR) in Orlando, Florida […]
11 Nov, 2022
MiNA Therapeutics presents positive Phase 1b data on MTL-CEBPA in combination with anti-PD1 checkpoint inhibitor
Clinical proof of mechanism established as an anti-cancer immunotherapy combination. Tumour responses observed in indications with primary resistance to checkpoint inhibitors […]
11 Apr, 2022
MiNA Therapeutics presents proof of mechanism data on MTL-STING as a novel cancer immunotherapy
MTL-STING is the second drug candidate to be advanced from the Company’s internal pipeline of small activating RNA therapeutics. STING is a highly validated drug target that plays a key role in immune evasion in cancer […]
25 Jan, 2022
First patient dosed in randomised Phase 2 clinical trial of MTL-CEBPA in patients with advanced liver cancer
MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA (RNAa) therapeutics, announces that it has dosed the first patient in a global Phase 2 clinical trial (OUTREACH-2) of MTL-CEBPA in combination with second line standard of care sorafenib (a tyrosine kinase inhibitor (TKI)) in advanced hepatocellular carcinoma (HCC or liver cancer) […]
21 Dec, 2021
MiNA Therapeutics appoints two Independent Directors with extensive industry experience to support next phase of growth
MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA (RNAa) therapeutics, announces the expansion of its Board, with the appointment of Susan Clement-Davies and Professor Sir Robert Lechler as Independent Directors, effective 1 January 2022 […]
01 Dec, 2021
National University Cancer Institute, Singapore and MiNA Therapeutics announce initiation of a Phase 1 clinical study of MTL-CEBPA in combination with first-line standard of care in advanced liver cancer
The National University Cancer Institute, Singapore (“NCIS”) and MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA therapeutics, announce that the first patient has been dosed in an investigator-sponsored Phase 1 study of MiNA’s small activating RNA oligonucleotide, MTL-CEBPA, in combination with first-line standard of care, atezolizumab and bevacizumab, in patients with previously untreated, advanced hepatocellular carcinoma (HCC). Atezolizumab and bevacizumab are being provided by F. Hoffmann-La Roche, Ltd (“Roche”) who is also supporting the study […]
12 Nov, 2021
MiNA Therapeutics highlights clinical data supporting the further development of MTL-CEBPA as an anti-cancer immunotherapy
MiNA Therapeutics Limited, the pioneer in small activating RNA (saRNA) therapeutics, announces positive safety data from the Phase 1a/b TIMEPOINT study of MTL CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours. The data will be initially presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place on 10-14 November 2021. Separately, MiNA also highlights the publication of positive data in the peer-reviewed journal Clinical Cancer Research […]
12 Nov, 2021
MiNA Therapeutics to present at Jefferies 2021 London Healthcare Conference
MiNA Therapeutics Limited, the pioneer in small activating RNA (saRNA) therapeutics, announces that its Chief Executive Officer, Robert Habib, will present and host one-on-one meetings at the Jefferies 2021 London Healthcare Conference, taking place from 16-19 November 2021 in-person and virtually […]
12 Oct, 2021
MiNA Therapeutics expands senior leadership team with four new hires to support next phase of growth
MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces that it has significantly expanded its senior leadership team with four new appointments to support the Company’s next phase of growth. These appointments include Troels Koch, Senior Vice President, Chemistry; Julia Vassiliadou, Vice President, Clinical Operations; Ilian Tchakov, Vice President, Clinical Development; Kevin Fettes, Vice President, Chemistry, Manufacturing and Controls, and Quality Operations […]
06 Jul, 2021
MiNA Therapeutics announces equity investment from Lilly
MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces that Eli Lilly and Company has entered into a definitive agreement under which it will make a direct equity investment in MiNA. The equity investment of approximately $15m follows the recent agreement between the two companies to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform, announced on 11 May 2021 […]
11 May, 2021
Lilly and MiNA Therapeutics Announce saRNA Research Collaboration
09 Apr, 2021
MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination Treatment
MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced translational data supporting the favourable immunological effects of MTL-CEBPA and its benefits in combination with other cancer therapies including anti-PD1 checkpoint inhibition. The studies combine pre-clinical research conducted at the Wistar Institute as well as biomarker analysis of the previously completed OUTREACH clinical trial […]
21 Jan, 2021
Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases
Servier, a global and independent pharmaceutical Group and MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today a research partnership to identify and develop small activating RNA (saRNA) therapies for the treatment of neurological disorders […]
05 Jan, 2021
MiNA Therapeutics Appoints Robin Wright as Chief Financial Officer
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the appointment of Robin Wright as Chief Financial Officer (CFO), effective January 04, 2021. Mr Wright joins MiNA from his most recent position as CFO at Pharming Group NV, a publicly listed, innovative biopharmaceutical company. At MiNA, he will use his deep expertise in the financial and biotechnology industries to lead the Company’s fundraising and financial control activities. He will be based at the Company’s headquarters in London […]
29 Sep, 2020
MiNA Therapeutics Appoints Peter Bains as Chief Business Officer
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the appointment of Peter Bains as Chief Business Officer (CBO), effective September 22, 2020. Mr Bains currently serves on MiNA’s Board of Directors as Non Executive Director and will retain this position while joining MiNA’s senior leadership team. With more than three decades of experience in the global pharmaceutical industry, he will leverage his years of expertise to lead the Company’s business development and corporate strategy activities […]
10 Sep, 2020
MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the completion of a £23 million ($30 million) Series A equity financing led by aMoon, Israel’s largest healthtech and life sciences venture fund, with participation from existing investors. The proceeds from the financing will be used to advance MiNA’s pipeline of proprietary, first-in-class, small activating RNA (“saRNA”) therapeutics, and to support the continued clinical development of MiNA’s lead candidate, MTL-CEBPA, as a combination treatment in cancer. As part of the Series A financing, Dr. Gur Roshwalb, M.D., M.B.A., Managing Director at aMoon, has joined the Board of Directors at MiNA Therapeutics. MTS Securities, LLC acted as the exclusive placement agent in connection with the financing […]
29 May, 2020
MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL CEBPA in Combination with Sorafenib in Liver Cancer at 2020 ASCO Annual Meeting
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today top line results from the Phase Ib dose escalation and cohort expansion study, OUTREACH, of lead candidate MTL-CEBPA in combination with sorafenib standard of care in patients with advanced hepatocellular carcinoma (HCC or liver cancer). The study met its primary endpoints of safety and tolerability for MTL CEBPA administered either concomitantly or sequentially with sorafenib. In addition, five patients experienced objective tumour responses, including two complete responses during the combination treatment […]
27 May, 2020
MiNA Therapeutics Announces Publication of Phase I Liver Cancer Data in Clinical Cancer Research and Provides Update on Clinical Development and Drug Discovery Programs
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the publication of data from its Phase I liver cancer trial, OUTREACH, in Clinical Cancer Research. It is the first publication in which a small activating RNA treatment (MTL-CEBPA) demonstrated clinical benefit. In addition, the Company provided an update on its ongoing clinical trials for lead program MTL-CEBPA and its drug discovery programs […]
03 March, 2020
MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL-CEBPA in Combination with anti-PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumours
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the initiation and first patient treated in TIMEPOINT, a global Phase 1/1b clinical study of MTL-CEBPA in combination with anti-PD1 checkpoint inhibitor pembrolizumab in patients with advanced solid tumours. The study is designed to assess the safety, tolerability, pharmacology and clinical activity of MTL-CEBPA in combination with pembrolizumab in these patients […]
07 January, 2020
MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the initiation of a research collaboration with AstraZeneca to evaluate small activating RNA (“saRNA”) molecules in metabolic diseases. The collaboration combines MiNA’s leading expertise in the discovery and development of saRNA therapeutics with AstraZeneca’s experience in identifying and bringing breakthrough treatments to patients with metabolic diseases […]
30 September, 2019
MiNA Therapeutics Presents Clinical and Pre-Clinical Data at ESMO Supporting MTL-CEBPA as Immunological Combination Treatment
MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, today announced final Phase 1 clinical data of MTL-CEBPA as a single agent in patients with advanced liver cancer as well as pre-clinical data demonstrating synergistic immunological and anti-tumour activity of MTL-CEBPA in combination with anti-PD1 checkpoint inhibition. The data will be presented in two posters at the European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain on September 28th and September 30th […]
02 April, 2019
MiNA Therapeutics Presents Pre-Clinical Data Supporting Combination of MTL-CEBPA with Sorafenib and Other Cancer Treatments at AACR
MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, today announced pre-clinical data supporting the immunological effects of MTL-CEBPA and its benefits in combination with other anti-cancer interventions including sorafenib, anti-PD1 checkpoint inhibition and radiofrequency ablation. The data will be presented today in two posters at the 2019 American Association for Cancer Research (AACR) Annual Meeting taking place in Atlanta, Georgia […]
19 December, 2018
MiNA Therapeutics Announces Enrolment of Patients in Expansion of Phase Ib Trial Evaluating MTL-CEBPA in Combination with Sorafenib
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today enrolment of the first patients treated with MTL-CEBPA in combination with Sorafenib in OUTREACH, the multi-centre Phase 1b clinical trial in patients with advanced liver cancer. The study is designed to assess the safety, tolerability and clinical activity of MTL-CEBPA in combination with Sorafenib. OUTREACH is currently being conducted at multiple clinical trials sites in the United Kingdom, Singapore and Taiwan […]
18 October, 2018
MiNA Therapeutics Announces Sosei Will Not Exercise Acquisition Option
MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced that Sosei Group Corporation (“Sosei”) has decided for strategic reasons not to exercise its option to acquire MiNA. The decision to relinquish these rights, which expire after October 18, 2018, is a result of Sosei’s strategic prioritisation. Sosei will retain their minority investment in MiNA Therapeutics based on their 2017 equity investment […]
19 September, 2018
MiNA Therapeutics Announces Findings From MTL-CEBPA Clinical Trial in Patients with Advanced Liver Cancer at International Liver Cancer Association Conference
MiNA Therapeutics, the pioneer in RNA activation therapeutics, provided yesterday an update from the ongoing Phase I study of small activating RNA (saRNA) candidate MTL-CEBPA in advanced liver cancer patients. The Chief Investigator of the trial reported observations of tumour responses in three patients when administered approved liver cancer therapies subsequent to treatment with MTL-CEBPA […]
04 June, 2018
MiNA Therapeutics Presents Initial Results from First-in-Human MTL-CEBPA Study in Advanced Liver Cancer Patients
MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, today announced preliminary results from its ongoing Phase I study of small activating RNA (saRNA) candidate MTL-CEBPA in advanced liver cancer. In the study, MTL-CEBPA was generally well tolerated in patients with both healthy and impaired liver function and provided evidence of anti-tumour activity. MTL-CEBPA was […]
16 May, 2018
MiNA Therapeutics to Present Initial Results from First-in-Human MTL-CEBPA Study at the 2018 ASCO Annual Meeting
MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced that it will present preliminary results from its Phase I study of small activating RNA (saRNA) candidate MTL-CEBPA in liver cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from June 1 – 5. The data will be […]
09 March, 2018
MiNA Therapeutics Announces Publication of Pre-Clinical Data Supporting Therapeutic Potential of Clinical Candidate MTL-CEBPA in Liver Cancer and Liver Disease
MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the publication of pre-clinical data on its MTL-CEBPA program in which the compound was shown to promote disease reversal in several models of liver disease and to reduce tumour burden in a model of liver cancer. MTL-CEBPA consists of CEBPA-51 small activating RNAs encapsulated in […]
08 November, 2017
Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases
Boehringer Ingelheim and MiNA Therapeutics (“MiNA”), a pioneer in RNA activation therapeutics, today announced that they have signed a collaboration and licensing agreement focused on the development of novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA’s small activating RNA (“saRNA”) therapeutics platform. The new partnership underscores Boehringer Ingelheim’s commitment to […]
02 November, 2017
Innovate UK Awards Grant to MiNA Therapeutics and LGC LINK
MiNA Therapeutics, the pioneer in RNA activation therapeutics, and LGC LINK, the oligonucleotide synthesis reagent manufacturer, and part of the Genomics division of LGC, today announced that Innovate UK has awarded the two companies a grant to develop liver targeted gene activation therapies for the treatment of liver diseases. The grant of up to approximately […]
06 September, 2017
MiNA Therapeutics Announces Publication of Pre-Clinical Data Supporting On-Target Mechanism of Action of Clinical Candidate MTL-CEBPA
MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the publication of new pre-clinical data supporting the on-target mechanism of action of drug candidate MTL-CEBPA. MTL-CEBPA is the first development candidate to emerge from MiNA’s RNA activation platform, consisting of CEBPA-51 small activating RNAs encapsulated in SMARTICLES® nanoparticles, and is currently being evaluated in […]
3 May, 2017
Sosei Pays GBP 35 Million for an Equity Stake and Acquisition Option Agreement in MiNA Therapeutics
Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) and MiNA Therapeutics Limited (“MiNA”) announced today that the companies have entered into a definitive agreement under which Sosei will make an investment in and acquire an exclusive option to potentially acquire MiNA Therapeutics, a private UK biopharmaceutical company and pioneer in RNA activation therapeutics (small activating […]